You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Previously untreatable lung cancer patients offered new therapy

The National Institute for Health and Care Excellence (NICE) has published a final appraisal document recommending Amgen’s Lumykras (sotorasib) for use within the Cancer Drugs Fund, for treating a type of lung cancer in adults whose disease has progressed or who cannot tolerate chemotherapy.